0000000000347009

AUTHOR

Alfonso Iorio

0000-0002-3331-8766

showing 10 related works from this author

Psychosocial aspects of haemophilia: a systematic review of methodologies and findings

2011

Psychosocial factors have a significant impact on quality of life for patients with chronic diseases such as haemophilia. Interventions to support the psychosocial needs of patients and their families, such as offering information and assistance, clarifying doubts, and teaching coping strategies to minimize the impact of disabilities, may help to maximize patient outcomes and improve quality of life for their families. The aim of this study was to evaluate the current literature on psychosocial aspects of haemophilia. Literature searches were performed using the PubMed database to identify studies evaluating psychosocial stressors in persons with haemophilia. Articles pertaining to the HIV …

Gerontologymedicine.medical_specialtySocial stigmabusiness.industryHaemophilia AMEDLINEPsychological interventionHematologyGeneral MedicineHaemophiliamedicine.diseaseQuality of life (healthcare)medicinebusinessPsychiatryPsychosocialGenetics (clinical)Qualitative researchHaemophilia
researchProduct

Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis.

2010

Long-term anticoagulant treatment is highly effective in preventing recurrent Venous Thrombo-Embolism (VTE) in patients with idiopathic Deep Vein Thrombosis (DVT) of the lower limbs, though associated with an increased risk for major bleeding that may offset the benefits of anticoagulation. Accordingly to recent guidelines, patients with idiopathic DVT should be treated for at least 3 months and then should be evaluated for the risk-benefit ratio of long-term therapy. However, such ‘time for decision’ is often unclear and the optimal duration of VKA remains debatable. In recent studies, markers for the assessment of the individual risk for recurrent thrombosis have been proposed, which can …

medicine.medical_specialtyVitamin Kmedicine.drug_classDeep veinDrug Administration ScheduleFibrin Fibrinogen Degradation ProductsRisk FactorsNeoplasmsDrug DiscoveryD-dimerSecondary PreventionHumansMedicineUltrasonographyVenous ThrombosisPharmacologyFirst episodebusiness.industryVascular diseaseAnticoagulantAnticoagulantsresidual vein thrombosis anticoagulant therapymedicine.diseaseThrombosisSurgeryVein thrombosisVenous thrombosismedicine.anatomical_structurebusiness
researchProduct

Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor A Systematic Review

2010

Background We aimed to determine the risk of recurrence for symptomatic venous thromboembolism (VTE) provoked by different transient risk factors. Data Sources MEDLINE, EMBASE, and Cochrane Collaboration Registry of Randomized Trials databases were searched. Study Selection Prospective cohort studies and randomized trials of patients with a first episode of symptomatic VTE provoked by a transient risk factor and treated for at least 3 months were identified. Data Extraction Number of patients and recurrent VTE during the 0- to 12-month and 0- to 24-month intervals after stopping therapy, study design, and provoking risk factor characteristics were extracted. Data Synthesis Annualized recurr…

medicine.medical_specialtyRate ratioRisk Assessmentlaw.inventionRandomized controlled triallawRecurrenceRisk FactorsInternal medicineEpidemiologyInternal MedicinemedicineHumansRisk factorProspective cohort studyFirst episodebusiness.industryIncidence (epidemiology)IncidenceVenous Thromboembolismvenous thrombosis recurrent eventmedicine.diseasePrognosisSurgeryVenous thrombosisbusiness
researchProduct

Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).

2009

A current goal of the Italian Society for Thrombosis and Haemostasis (SISET) is the production of guidelines for clinical conditions related to haemostasis and thrombosis. In 2006, the Executive Committee of SISET adopted a new program for the production of methodologically and scientifically sound guidelines aimed at both addressing clinical practice and stimulating new research. The first major step for this program was to train methodologists to manage working groups that compose the guidelines, and to create a reference document that describes the development of the program. The aim of the present paper is to report a short version of this methodological document, for those who wish to …

Medical educationReference DocumentHemostasisbusiness.industryThrombosisHematologyGuidelineSettore MED/15 - Malattie Del SangueClinical Practiceguidelines methodologyGuideline implementationItalyMultidisciplinary approachEVIDENCE BASED MEDICINEPractice Guidelines as TopicMedicineHumansGuideline developmentGrading (education)businessWorking groupThrombosis research
researchProduct

Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study.

2011

Abstract The safest duration of anticoagulation after idiopathic deep vein thrombosis (DVT) is unknown. We conducted a prospective study to assess the optimal duration of vitamin K antagonist (VKA) therapy considering the risk of recurrence of thrombosis according to residual vein thrombosis (RVT). Patients with a first unprovoked DVT were evaluated for the presence of RVT after 3 months of VKA administration; those without RVT suspended VKA, while those with RVT continued oral anticoagulation for up to 2 years. Recurrent thrombosis and/or bleeding events were recorded during treatment (RVT group) and 1 year after VKA withdrawal (both groups). Among 409 patients evaluated for unprovoked DVT…

AdultMalemedicine.medical_specialtyVitamin Kmedicine.drug_classDeep veinHemorrhageDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRecurrenceRisk Factorsdeep vein thrombosis (DVT)Residual vein thrombosismedicineHumansProspective Studiesdeep vein thrombosis (DVT); vitamin K antagonist (VKA) therapy; Residual vein thrombosisProspective cohort studyAgedUltrasonographyVenous Thrombosisbusiness.industryAcenocoumarolAnticoagulantsHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryClinical trialVein thrombosisvitamin K antagonist (VKA) therapymedicine.anatomical_structureLower ExtremityRelative riskFemaleWarfarinbusiness
researchProduct

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.

2019

Abstract The objective of this scoping review is to summarize the current use of pharmacokinetics for tailoring prophylaxis in hemophilia patients switching between clotting factor products. Patients with hemophilia may require switching of clotting factor concentrates due to a variety of factors, but there have been perceived risks associated with switching, such as inhibitor development or suboptimal protection due to inadequate dosing while titrating treatment. Studies that look at patients switching from one clotting factor concentrate to another are categorized in terms of their primary and/or secondary objectives, notably biosimilarity and comparative pharmacokinetic studies and inhib…

medicine.medical_specialtyFactor concentrate610 Medicine & healthReview Article030204 cardiovascular system & hematologyHemophilia ADrug SubstitutionHemophilia BFactor IX03 medical and health sciencesDrug substitution0302 clinical medicinePharmacokineticsmedicineDosingIntensive care medicineFactor IXClotting factorOriginal Articles: Haemostasisfactor IXFactor VIIIlcsh:RC633-647.5business.industryDosing regimenlcsh:Diseases of the blood and blood-forming organsHematology3. Good healthOnline‐only Articlesfactor VIII3121 General medicine internal medicine and other clinical medicinedrug substitution10032 Clinic for Oncology and Hematologydrug substitution; factor IX; factor VIII; hemophilia A; hemophilia Bhemophilia Bhemophilia Abusiness030215 immunologymedicine.drug
researchProduct

Drug-drug interactions in a cohort of hospitalized elderly patients

2013

Purpose The aim of this study is to assess the prevalence of patients exposed to potentially severe drug–drug interactions (DDIs) at hospital admission and discharge and the related risk of in-hospital mortality and adverse clinical events, readmission, and all-cause mortality at 3months. Methods This cross-sectional, prospective study was held in 70 Italian internal medicine and geriatric wards. Potentially severe DDIs at hospital admission and discharge; risk of in-hospital mortality and of adverse clinical events, readmission, and all-cause mortality at 3-month follow-up. Results Among 2712 patients aged 65years or older recruited at hospital admission, 1642 (60.5%) were exposed to at le…

Drugmedicine.medical_specialtyPediatricsMultivariate analysisEpidemiologybusiness.industryClinical eventsmedia_common.quotation_subjectOdds ratioPharmacoepidemiologyConfidence intervalEmergency medicineCohortMedicinePharmacology (medical)businessProspective cohort studymedia_commonPharmacoepidemiology and Drug Safety
researchProduct

Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multip…

2020

Contains fulltext : 232738.pdf (Publisher’s version ) (Closed access) BACKGROUND: Pulmonary embolism (PE)-related mortality is decreasing in Europe. However, time trends in the USA and Canada remain uncertain because the most recent analyses of PE-related mortality were published in the early 2000s. METHODS: For this retrospective epidemiological study, we accessed medically certified vital registration data from the WHO Mortality Database (USA and Canada, 2000-17) and the Multiple Cause of Death database produced by the Division of Vital Statistics of the US Centers for Disease Control and Prevention (CDC; US, 2000-18). We investigated contemporary time trends in PE-related mortality in th…

MaleVascular damage Radboud Institute for Health Sciences [Radboudumc 16]computer.software_genre0302 clinical medicineRisk FactorsCause of DeathEpidemiologyMedicine030212 general & internal medicineYoung adultChildCOVIDCause of deathAged 80 and overeducation.field_of_studyDatabaseMortality rateAge FactorsArticlesMiddle AgedPulmonary embolismDatabases as TopicChild PreschoolFemaleAdultPulmonary and Respiratory MedicineCanadamedicine.medical_specialtyAdolescentPopulation610 Medicine & healthSubgroup analysisWorld Health OrganizationYoung Adult03 medical and health sciencesSex FactorsHumanseducationAgedRetrospective Studiesbusiness.industry10031 Clinic for AngiologyInfant NewbornInfantRetrospective cohort studymedicine.diseaseUnited States030228 respiratory system2740 Pulmonary and Respiratory MedicinePulmonary Embolismbusinesscomputer
researchProduct

Heart failure and chronic kidney disease in a registry of internal medicine wards

2014

Background: The aim of the present study was to evaluate the association between heart failure (HF) and chronic kidney disease (CKD) in tertiary care centers using the clinical records of patients enrolled in internal medicine departments.Patients and methods: We used the clinical records of 1380 elderly patients to identify patients with a history of HF and CKD using admission ICD codes and glomerular filtration rate (GFR) formulas. Magnitude and strength of such associations were investigated by univariable and multivariable analysis.Results: Of the 1380 patients enrolled, 27.9% had HF (age 80 ± 7, BMI 27 ± 6 kg/m2) and 17.4% CKD (age 81 ± 7, BMI 26.8 ± 6 kg/m2). Both groups were signific…

medicine.medical_specialtyChronic kidney disease; Elderly; Heart failure; REPOSI; Gerontology; Geriatrics and GerontologyHeart failure; Elderly; Chronic kidney disease; REPOSIChronic kidney disease; Elderly; Heart failure; REPOSI; Humans; Sleep Apnea Syndromes; Noninvasive Ventilation; Gerontology; Geriatrics and GerontologyChronic kidney disease; Elderly; Heart failure; REPOSIRenal functionHeart failure; chronic kidney disease; elderly; registry; REPOSIHeart failureregistryTertiary careSleep Apnea SyndromeElderlySleep Apnea SyndromesInternal medicineChronic kidney diseaseEpidemiologymedicineHumansNoninvasive Ventilationbusiness.industryREPOSIChronic kidney disease; Elderly; Heart failure; REPOSI; Humans; Sleep Apnea Syndromes; Noninvasive Ventilation; Geriatrics and Gerontology; Gerontologymedicine.diseaseHeart failureHeart failure Elderly Chronic kidney disease REPOSIIcd codesGeriatrics and GerontologybusinessClinical recordBody mass indexGerontologyKidney diseaseHuman
researchProduct

Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behçet's disease and deep vein thrombosis

2004

Objective To evaluate the frequency and type of vascular lesions and to study the association of factor V gene G1691A (Leiden) and prothrombin gene G20210A polymorphisms with venous thrombosis in Italian patients with Behcet's disease (BD). Methods Included were 118 consecutive Italian BD patients followed over a 3-year period (1997–1999) who satisfied the International Study Group criteria for BD. The control group consisted of 132 healthy Italian blood donors. All BD patients and controls were genotyped by polymerase chain reaction and allele-specific restriction enzyme techniques for factor V Leiden and prothrombin gene G20210A polymorphisms. Results Vascular lesions were observed in 37 …

medicine.medical_specialtybiologybusiness.industryDeep veinImmunologyFactor VBehcet's diseasemedicine.diseaseGastroenterologyThrombophlebitisThrombosisVenous thrombosismedicine.anatomical_structureRheumatologyInternal medicineImmunologymedicinebiology.proteinFactor V LeidenImmunology and AllergyPharmacology (medical)cardiovascular diseasesbusinessAllele frequencyArthritis Care & Research
researchProduct